Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion

Eli Lilly (NYSE: LLY) is reportedly in advanced negotiations to acquire Kelonia Therapeutics in a deal valued at more than $2 billion, according to a Wall Street Journal report citing sources familiar with the matter. The potential acquisition could be announced as early as Monday, provided discussions remain on track. The agreement may also include additional milestone-based payments tied to future performance.

Kelonia Therapeutics, a privately held biotechnology company, is focused on developing innovative treatments for multiple myeloma, a type of blood cancer. The company’s core technology centers on a next-generation CAR-T therapy designed to reprogram a patient’s immune system to attack cancer cells more efficiently. Unlike traditional CAR-T approaches, Kelonia’s platform aims to simplify the process by potentially eliminating the need for chemotherapy and complex cell manufacturing, which could significantly reduce treatment costs and improve accessibility.

The biotech startup has raised just under $60 million in funding to date and was last valued at slightly above $100 million in 2022. If finalized, the acquisition would represent a substantial premium and highlight growing interest in advanced cancer therapies, particularly in the rapidly expanding hematologic oncology market.

For Eli Lilly, the deal aligns with its broader strategy of strengthening its oncology pipeline and expanding its footprint in high-growth therapeutic areas. The pharmaceutical giant has been actively pursuing acquisitions and partnerships, supported by strong revenue streams from its blockbuster diabetes and weight-loss drugs.

This potential acquisition underscores the increasing competition among major pharmaceutical companies to secure cutting-edge biotech innovations. Investors and market watchers are closely monitoring developments, as the deal could significantly impact Lilly’s long-term growth and position in the cancer treatment space.